

ASX Announcement

Imugene Announces Board Enhancement

Sydney, Australia, 26 May 2026: Imugene Limited (ASX:IMU) (“Imugene” or the “Company”) today announced that the Company has initiated a strengthening of the Board of Directors which includes the appointment of two new non-executive directors, Dr Charmaine Gittleson and Mr Michael Kotsanis.

Executive Chairman Paul Hopper said “I am delighted that Charmaine and Michael are joining the Board. Both have extensive biotech experience across multiple international and ASX companies and bring a myriad of skills to bear. Their appointments result in a stronger and more balanced Board, who will support management as we progress our exciting azer-cel technology through the clinic.”

Both appointments are effective from 30 June 2026.

Dr Charmaine Gittleson

Charmaine is a seasoned pharmaceutical physician and biopharmaceutical senior executive with over 20 years of global experience in drug development, clinical strategy, and regulatory affairs.

She served as Chief Medical Officer at CSL Limited, where she led global clinical and medical governance across a diverse portfolio of therapies, including rare diseases, immunology, and vaccines. Her leadership was instrumental in advancing CSL’s innovation pipeline and navigating complex global regulatory environments.

Since transitioning from executive leadership, Charmaine has held Non-Executive roles within a number of ASX-listed life sciences companies, mainly focused on oncology. She is currently Chair of Percheron Therapeutics (ASX:PER) and is a Non-Executive Director of PolyNovo (ASX:PNV) and George Medicines. She was previously on the Board of Patrys (ASX:PAB), providing strategic oversight on clinical development, regulatory strategy, and commercial growth.



Mr Michael Kotsanis

Michael brings 35 years operational leadership experience in global pharmaceutical markets, leading regional franchises at Hospira/Mayne Pharma (oncology injectables, US\$500M+ EMEA revenue) and Synthon (generics/biologics, €250M+ global revenue), driving commercialisation, licensing and market expansion.

He returned to Australia in 2014 to assume the CEO position at Acrux (ASX:ACR), directing pipeline development, business development, capital management/investor relations, and ASX/ASIC compliance for a topical pharmaceutical product developer.

Throughout his career he has held numerous Executive Director appointments – on the main Board of Synthon (private) and various operating subsidiaries of the listed companies.

Michael is a Non-Executive Director at ICE Pharma, a private equity owned, Italian specialty pharmaceutical company that manufactures active pharmaceutical ingredients. He was formerly a Non-Executive Director at IDT Australia (ASX:IDT) where he was also Chair of the Human Capital/Remuneration Committee and an Audit/Risk Committee member.

Post restructuring, the Board will be comprised of Australian biotech leaders, medical oncologists, as well as experienced US biotech executives with NASDAQ experience.

The newly constituted Board is currently considering the Board sub-committee composition in accordance with the ASX Corporate Governance Principles and Recommendations, and will provide details in due course.

Imugene also advises that the Remuneration Committee has initiated a number of actions and reviews in response to the Remuneration Strike received at the Company's Annual General Meeting held in November 2025.

The Remuneration Committee has determined that there will be no salary increases for Chair and CEO & Managing Director; the Board and CEO & Managing Director will forego



50% of their entitlement to long term equity incentives; the Chair and CEO & Managing Director have re-invested up to 50% of their 2025 bonus in on-market share purchases (see ASX 3Y releases on 15th and 18th May 2026).

In addition, a comprehensive review of the Company's remuneration policies and framework will be complete ahead of the 2026 Annual General Meeting.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

General Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
communications@imugene.com

Connect with us on LinkedIn @Imugene Limited
Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and together with leading specialists and medical professionals, we believe Imugene's cellular therapy may become foundation treatments for cancer. Our goal is to ensure that Imugene is at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.